Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans

Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with rifampin–streptomycin or rifampin–clarithromycin daily for 8 weeks recommended by World Health Organization (WHO). These options are lengthy with severe side effects. A new anti-tuberculosis drug, TB47, targeting QcrB in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yamin, Hameed, H.M. Adnan, Liu, Yang, Guo, Lingmin, Fang, Cuiting, Tian, Xirong, Liu, Zhiyong, Wang, Shuai, Lu, Zhili, Islam, Md Mahmudul, Zhang, Tianyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982501/
https://www.ncbi.nlm.nih.gov/pubmed/33777679
http://dx.doi.org/10.1016/j.apsb.2020.11.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982501/
https://www.ncbi.nlm.nih.gov/pubmed/33777679
http://dx.doi.org/10.1016/j.apsb.2020.11.007

Ejemplares similares